期刊文献+

心钠素对多发性骨髓瘤细胞增殖的影响及作用机制探讨 被引量:3

The effects of atrial natriuretic peptide in proliferation of myeloma cells and its potenial mechanisms
下载PDF
导出
摘要 目的:探讨心钠素(atrial natriuretic peptide,ANP)对多发性骨髓瘤细胞株(MM1.S)的增殖抑制及其作用机制。方法:MM1.S置于含10%胎牛血清的RPMI1640培养基培养,ANP浓度分别为1、10、50及100μmol/L。收集各组不同培养时间(24、48、72 h)细胞,CKK-8方法检测细胞的增殖抑制作用,流式细胞术检测细胞周期,Western blot法检测MM1.S细胞NPR-A、NPR-C蛋白的表达,qRT-PCR检测不同浓度ANP作用MM1.S细胞24 h后miR-21的表达。结果 :ANP对MM1.S细胞具有增殖抑制作用,且呈浓度依赖性(P<0.01)。细胞周期检测为G1期细胞比例较对照组明显增加(P<0.01),S期、G2期细胞比例下降(P<0.05),4个浓度组间两两比较有统计学差异(P<0.05)。MM1.S细胞存在NPR-A、NPR-C蛋白的表达。ANP不同浓度(1.0,10,50,100μmol/L)作用MM1.S细胞24 h后miR-21表达下调,相对表达量较阴性对照组分别下降了8.6%、24.2%、37.5%和49%(P<0.05)。结论:ANP能抑制MM1.S增殖,其作用机制可能是通过阻滞细胞周期于G1期和下调miR-21表达发挥其抗肿瘤效应。 Objective To study the effects of atrial natriuretic peptide (ANP) in proliferatiin inhibit and mechanism of myeloma cells (MM1.S). Methods The human MM1.S cells were placed in RPMI1640 containing 10% FBS and incubated in cell incubator. The ANP concentration were 1.0, 10, 50 and 100 μmol/L, and each group had different incubation time (0,24,48,72 h) respetively. CCK-8 assay was used to detect the inhibition of ANP on MM1.S cell proliferation. The flow cytometry was used to analyze the cell cycle of MM1.S. The Western blotting was needed to detect whether the natriuretic peptide receptor-A (NPR-A, NPR-C) were expressed in MM1. S cells. The qRT-PCR was employed to analyze expression levels of miR-21 in MM1.S with various concentrations of ANP for 24 h. Results ANP could inhibit proliferation of MM1.S in significantly dose-dependent manner (P 〈 0.01) ,and the inhibition was the most obvious after treated with ANP by 24 hours. Percentage of cells in G1 phase increased significantly accompanying cell cycle arrest in G1 phase comparing with the control group (P 〈 0.01), while the percentage of S and G2 phase cells decreased(P 〈 0.05). Significant differences were observed among the four ANP-treated MM1.S cells groups (P 〈 0.05). Natriuretic peptide receptor (NPR-A/C) were expressed in MM1. S cells. After the treatment of 1.0, 10, 50 and 100 μmol/L ANP in MM1.S cells for 24 h, qRT-PCR examination indicated that miR-21 was down-regulated comparing with the control group (P 〈 0.05). ANP concentration in the four groups reduced the expression of miR-21 by 8.6%, 24.2%, 37.5%and 49% respectively. Conclusion ANP has anti-proliferative effect in myeloma cells by blocking cell cycle in G1 phase and inhibiting the miR-21 expression.
出处 《实用医学杂志》 CAS 北大核心 2015年第14期2268-2271,共4页 The Journal of Practical Medicine
基金 国家自然科学基金项目(编号:81460037) 江西省自然科学基金项目(编号:20122BAB205022)
关键词 心钠素 多发性骨髓瘤细胞 细胞增殖 MIR-21 Atrial natriuretic peptide MM1.S cells Cell proliferation MiR-21
  • 相关文献

参考文献13

  • 1丁江华,孔春芳,袁利亚,陈国安.Akt依赖性与多发性骨髓瘤耐药[J].实用医学杂志,2013,29(4):667-669. 被引量:2
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics [J]. CA Caucer J Clin, 2012,62( 1 ) : 10-29.
  • 3Vesely DL. Atrial Natriuretie Peptide prohormone gene expression: hormones and diseases that upregulate its expression [J]. I13BMB Life, 2002,53(3):153-159.
  • 4Vesely B, McAfee Q, Gower W, et al. f%ur peptides decrease the number of hmnan pancreatic adenocareinoma cells [J]. Eur J Clin Invest, 2003,33 ( 11 ) : 998-1005.
  • 5Vesely BA, Song S, Sanehez-Ramos, et al. Four peptide hormones demase the number of human breast adenoeareinoma cells [J]. Ear J Cliu Invest, 2005,35( 1 ) : 60-69.
  • 6Wildes TM, Vii R, Petersdoff SH, et al. New treatment approaches for older adults with multiple myeloma [J]. J Geriatr Oncol, 2012,3 ( 3 ) : 279-290.
  • 7徐秀月,王凌云,姜秀春,彭大影,王德军.硼替佐米治疗多发性骨髓瘤疗效及影响因素分析[J].实用药物与临床,2012,15(9):561-563. 被引量:9
  • 8Vesely DL. Cardiac hormones for the treatment of cancer [J]. Endocr Relat Cancer, 2013,20(3) :R113-125.
  • 9Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival [J ]. Bin1 Direct, 2011,6 : 23.
  • 10Zhang T, Sun L, Wang S, et al. Expression of miR-21 in muhiple myeloma and its clinical significance [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2012,20(3) :616-619.

二级参考文献37

  • 1Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks ad transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected coloreetal eancer[J]. Cancer,2007,110 (8) :1697-1707.
  • 2Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression[J]. Cell, 2008,133 (3) : 403-414.
  • 3Hwang JH, Voortman J, Giovannetti E, et al. Identification of microR- NA-2 as a biomarker for chemoresistance and clinical outcome followillg adjuvant therapy in resectable pancreatic cancer[J]. PLOS One, 2010,5 (5) :e10630.
  • 4Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time- to-event analyses of the multicenter phase 2 PINNACLE study [J]. Ann Oncol,2009,20(3) :520-525.
  • 5Ghosh N, Ye X, Ferquson A, et al. Bortezomib and thalido- mide. a steroid free regimen in newly diagnosed patients with multiple myeloma [ J ]. Br J Haematol, 2011,152 ( 17 ) : 593-598.
  • 6Siegel R,Naishadham D,Jemal A. Cancer statistics,2012[J].CA:A Cancer Journal for Clinicians,2012,(01):10-29.
  • 7Martelli A M,Tahellini G,Bressanin D. The emerging multiple roles of nuclear Akt[J].Biochimica Et Biophysica Acta,2012,(12):2168-2178.
  • 8Ho Y P,Kuo C W,Hsu Y T. beta-Actin is a downstream effector of the PI3K/AKT signaling pathway in myeloma cells[J].Molecular and Cellular Biochemistry,2011,(1-2):129-139.
  • 9Steinbrunn T,Stuhmer T,Sayehli C. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma[J].British Journal of Haematology,2012,(04):430-440.
  • 10Alkan S,Izban K F. hmmunohistoehemical localization of phosphorylated AKT in multiple myeloma[J].Blood,2002,(06):2278-2279.

共引文献30

同被引文献22

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部